Neuraxis (NRXS) vs QT Imaging (QTI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Neuraxis (NRXS) has outperformed QT Imaging (QTI) over the past year, gaining 128.0% versus a loss of 92.0%. Neuraxis is the larger company by market cap ($87.0 million vs $39.2 million), about 2.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NRXS | QTI |
|---|---|---|
| Share price | $6.93 | $2.68 |
| Market cap | $87.03M | $39.23M |
| 1-day change | +2.36% | +3.08% |
| YTD return | +52.64% | -56.07% |
| 1-year return | +127.96% | -91.99% |
| EPS (TTM) | $-0.80 | $-1.40 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.33 | $36.75 |
| 52-week low | $2.21 | $2.42 |
| Distance from 52-week high | -25.72% | -92.71% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +58.73% | +288.06% |
| Average volume | 107.27K | 34.21K |
| Shares outstanding | 12.56M | 14.64M |
| Employees | 24 | 31 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Neuraxis is about 2.2 times larger than QT Imaging by market value ($87.03M vs $39.23M).
- NRXS has outperformed QTI by 219.9 percentage points over the past year.
About Neuraxis
NRXS stock →NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 8 years of age with functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD) and associated FD nausea symptoms.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 24 employees
About QT Imaging
QTI stock →QT Imaging Holdings, Inc. engages in the research, development, and commercialization of body imaging systems with low frequency sound waves for detection, diagnosis, and treatment of diseases in the United States and Internationally.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 31 employees
NRXS vs QTI FAQ
Which is bigger, Neuraxis or QT Imaging?
Neuraxis (NRXS) is larger, with a market capitalization of $87.03M compared with $39.23M for QT Imaging (QTI).
Which stock has performed better over the past year, NRXS or QTI?
NRXS returned +127.96% over the past 12 months, compared with -91.99% for QTI (price return, excluding dividends). Past performance does not predict future results.
Are Neuraxis and QT Imaging in the same industry?
Yes. Both are classified in the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry within the Health Care sector.